| Name | Kallikrein-9 | ||
| UniProt ID | KLK9_HUMAN | ||
| Gene Name | KLK9 | ||
| Gene ID | 284366 | ||
| Synonyms |
KLK9, KLK-L3, KLKL3
|
||
| Sequence |
MKLGLLCALLSLLAGHGWADTRAIGAEECRPNSQPWQAGLFHLTRLFCGATLISDRWLLT
AAHCRKPYLWVRLGEHHLWKWEGPEQLFRVTDFFPHPGFNKDLSANDHNDDIMLIRLPRQ ARLSPAVQPLNLSQTCVSPGMQCLISGWGAVSSPKALFPVTLQCANISILENKLCHWAYP GHISDSMLCAGLWEGGRGSCQGDSGGPLVCNGTLAGVVSGGAEPCSRPRRPAVYTSVCHY LDWIQEIMEN |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa284366 | ||
| Pfam | PF00089; PF05410 | ||
| Pair Name | Acteoside, Sorafenib | |||
| Phytochemical | Acteoside | |||
| Drug | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Down-regulation | Kallikrein-9 | Expression | |
| Result | Acteoside exerts an antitumor effect possibly through its up-regulation of p53 levels as well as inhibition of KLK expression and angiogenesis. Acteoside could be useful as an adjunct in the treatment of advanced HCC in the clinic. | |||
